【摘要】：醫(yī)藥行業(yè)不僅是高新技術(shù)產(chǎn)業(yè)以及戰(zhàn)略新興產(chǎn)業(yè)的重要組成部分，還是按國際標準劃分的15類國際化產(chǎn)業(yè)和世界貿(mào)易增長最快的朝陽產(chǎn)業(yè)之一，有著高技術(shù)、高投入、高風險和高回報的特點。同時，醫(yī)藥行業(yè)是河北省十大支柱產(chǎn)業(yè)之一，是重要的發(fā)展行業(yè)。在河北省的醫(yī)藥行業(yè)中，醫(yī)藥制造業(yè)占主導(dǎo)地位，本文研究重點是河北省的醫(yī)藥制造業(yè)。 在當前國內(nèi)外經(jīng)濟形勢錯綜復(fù)雜、市場競爭日益激烈和藥品政策性限價、各地“雙信封”制基藥招標政策等不確定因素下，河北省的醫(yī)藥制造業(yè)依然保持了規(guī)模穩(wěn)定增長，創(chuàng)新與結(jié)構(gòu)調(diào)整初顯成效的特點。但同時也面臨著許多挑戰(zhàn)，經(jīng)濟總量在全國位次后移，效益明顯下滑，出口形勢也不明朗。在《河北省醫(yī)藥產(chǎn)業(yè)發(fā)展“十二五”規(guī)劃》出臺，，大力發(fā)展醫(yī)藥行業(yè)的情況下，研究河北省如何應(yīng)對復(fù)雜的外界經(jīng)濟環(huán)境，調(diào)整其發(fā)展路徑保證收利同增有著重要的意義。 本文在產(chǎn)業(yè)競爭力相關(guān)理論的基礎(chǔ)上，首先對如何研究河北省醫(yī)藥制造業(yè)的競爭力進行了界定；然后運用綜合比較優(yōu)勢系數(shù)法、偏離-份額法以及因子分析法對河北省醫(yī)藥制造業(yè)的競爭力進行了分析；最后又引用華藥集團的案例，驗證了河北省醫(yī)藥制造業(yè)發(fā)展過程中的存在的問題。研究發(fā)現(xiàn)河北省醫(yī)藥制造業(yè)存在的問題有規(guī)模優(yōu)勢不明顯，結(jié)構(gòu)仍需調(diào)整；效益水平大幅下滑；創(chuàng)新水平不高等。 最后得出了以下結(jié)論：河北省醫(yī)藥制造業(yè)相較于其他主導(dǎo)產(chǎn)業(yè)不具有比較優(yōu)勢；河北省化學藥品原料藥制造業(yè)和中成藥生產(chǎn)制造業(yè)不具備競爭優(yōu)勢，化學藥品制劑業(yè)具有較強的競爭力，其他行業(yè)雖然具有一定的競爭力但規(guī)模很��；與醫(yī)藥強省相比，河北省醫(yī)藥制造業(yè)的競爭力處于劣勢地位。并針對以上結(jié)論，對今后的河北省發(fā)展醫(yī)藥制造業(yè)提出了相關(guān)建議，主要是調(diào)整產(chǎn)業(yè)結(jié)構(gòu)，降低大宗原料藥的比重，增加高附加值的生物制藥的生產(chǎn)；加大科研投入力度，提高行業(yè)的創(chuàng)新能力。
[Abstract]:The pharmaceutical industry is not only an important part of the high-tech industry and the strategic emerging industry, but also one of the 15 international industries and one of the fastest-growing sunrise industries in the world, which is divided according to international standards, with high technology and high input. The characteristics of high risk and high return. At the same time, the pharmaceutical industry is one of the ten pillar industries in Hebei Province, is an important development industry. In the pharmaceutical industry of Hebei Province, pharmaceutical manufacturing industry plays a leading role. This paper focuses on the pharmaceutical manufacturing industry in Hebei Province. In the current complex economic situation at home and abroad, the increasingly fierce market competition, the price limit of drug policy, and other uncertain factors, such as the bidding policy for "double envelopes" base medicines, the pharmaceutical manufacturing industry in Hebei Province has maintained a steady growth in scale. Innovation and structural adjustment show the characteristics of initial effect. But at the same time also faces many challenges, the total economic volume in the national position behind, the benefit obviously falls, the export situation is also unclear. With the introduction of the 12th Five-Year Plan for the Development of Pharmaceutical Industry in Hebei Province and the vigorous development of the pharmaceutical industry, it is of great significance to study how Hebei Province can cope with the complex external economic environment and adjust its development path to ensure the same increase in revenue and profits. Based on the theory of industrial competitiveness, this paper defines how to study the competitiveness of pharmaceutical manufacturing industry in Hebei Province, and then applies the method of comprehensive comparative advantage coefficient. The deviation-share method and factor analysis method are used to analyze the competitiveness of Hebei pharmaceutical manufacturing industry. Finally, the case of Chinese pharmaceutical group is cited to verify the existing problems in the development of pharmaceutical manufacturing industry in Hebei province. It is found that the problems of pharmaceutical manufacturing industry in Hebei Province are not obvious in scale advantage, structure still needs adjustment; the level of benefit falls sharply; and the level of innovation is not high. Finally, the following conclusions are drawn: the pharmaceutical manufacturing industry in Hebei Province has no comparative advantage over other leading industries, and the pharmaceutical and proprietary Chinese medicine manufacturing industries in Hebei Province do not have a competitive advantage. Chemical preparation industry has a strong competitiveness, although other industries have a certain competitiveness, but the scale is very small; compared with strong pharmaceutical provinces, Hebei Province's pharmaceutical manufacturing industry is in a disadvantaged position. In view of the above conclusions, this paper puts forward some relevant suggestions for the development of pharmaceutical manufacturing industry in Hebei Province in the future, mainly to adjust the industrial structure, reduce the proportion of bulk API, increase the production of high value-added biopharmaceuticals, and increase the investment in scientific research. Improve the innovation ability of the industry.
【學位授予單位】：河北經(jīng)貿(mào)大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：F426.72

【引證文獻】

相關(guān)期刊論文 前2條

1 孫志穎;司賀龍;王秀伶;楊學舉;;基于“實踐能力培養(yǎng)路線圖”的本科專業(yè)改革——以河北農(nóng)業(yè)大學制藥工程專業(yè)為例[J];河北農(nóng)業(yè)大學學報(農(nóng)林教育版);2015年02期

2 杜宏巍;王文超;;河北省醫(yī)藥制造產(chǎn)業(yè)發(fā)展現(xiàn)狀分析及對策建議[J];中國市場;2015年30期

本文編號：2188416